A 24-month Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Efficacy Safety Tolerability Biomarker and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to determine if AZD3293 is effective and safe in treating early Alzheimer?s disease compared with placebo, and to determine if AZD3293 has an effect on biomarkers.
Description
The purpose of this study is to evaluate the potential of AZD3293 to be a disease-modifying treatment for early Alzheimer's disease by providing evidence of the compound's safety, tolerability, and impact on cognitive decline and on biomarkers relevant to AD in subjects with early AD.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 55 Years - 85 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1511947211
